First-line lung cancer: can Keytruda be stopped?

Thumbnail
Thumbnail
Thumbnail

Only one near-term event remains to determine whether Keytruda will face any kind of challenge in first-line NSCLC.

2018 started with the promise of a first-line lung cancer shakeout but it looks likely to end with Merck & Co’s Keytruda even more entrenched than before.

This report into the first-line NSCLC space discusses key upcoming trial readouts and regulatory decisions. Vantage puts into context the developments that over recent months have seen Keytruda consolidate its dominant position.

 

Download Report